Home Blog Page 13

Rokid Leads Global AR and AI Glasses Shipments as AI Glasses Market Surges in H1 2026

NEW YORK, Sept. 29, 2026 /PRNewswire/ — Rokid ranked No. 1 worldwide in the AR and AI Glasses segment by shipment share in H1 2026, accounting for 41 percent of all products shipped within the category, according to a new report by Counterpoint Research. This finding further validates Rokid as one of the leaders in an emerging product segment. This success builds on the year-on-year sales momentum Rokid established last year, when Counterpoint Research named the company the leading waveguide-based AR glasses OEM by shipments in H2 2025.

Shipments for smart glasses are surging globally as wearables turn from a novelty to a commodity. The Counterpoint Research report found that global AI Glasses shipments surged by 263 percent year over year in H1 2026. While displayless smart glasses still accounted for a majority of the shipments, AR and AI glasses shipments surged by 449 percent YoY, signaling rising consumer interest.

“The bigger story beneath the numbers is that consumers want their wearables to do more,” said Zoro Shao, Rokid Group Vice President and Global General Manager. “Rokid is at an inflection point where our mature software ecosystem, robust hardware, and lightweight design can meet mainstream use cases–and we’re glad to see this data that shows consumers are taking notice. Also noteworthy is that our recent focus on enabling new agentic experiences aligns with the report’s conclusion that agentic AI glasses will drive the next phase of growth.”

Rokid’s display-enabled glasses use a waveguide projection system to deliver information in the wearer’s field of view, minimizing distractions caused by checking a smartphone. Capable of real-time translation, navigation, teleprompting, and other features, Rokid smart glasses simplify tasks in both professional and personal settings. They also stand out by including OpenAI ChatGPT, Google Gemini, DeepSeek, and Qwen on a single device. Combining their intelligence with its embedded first-person camera, Rokid smart glasses can provide information on what the wearer is seeing and even help people with visual impairments stay aware of their environments and help them reclaim their autonomy.

Rokid smart glasses have also overcome the long-standing challenge of uncomfortable and unappealing frame designs. The Rokid Glasses weigh just 49 grams and are just as easy to wear as regular glasses. They also support a wide range of prescription lenses via a snap-on lens system.

The combination of hardware and software features has contributed to Rokid’s global success. Beyond North America and China, Rokid has recently landed in key European markets, including Germany and France, by partnering with local retailers and launching its dedicated websites. To date, Rokid’s developer community has grown to 35,000 global members. To help them easily create new smart glasses, Rokid recently announced the global availability of its AIUI Studio, a browser-based development platform, at IFA Berlin 2026.

About Rokid

Founded in 2014, Rokid is a global pioneer in augmented reality (AR) and AI, creating human-centered smart glasses that integrate intelligence seamlessly into everyday life. The company has introduced a range of innovations across AI and AR hardware, including the first open AI ecosystem for wearables, dual-chip architecture, multilingual voice interaction, intuitive AI shortcuts, and mass-produced smart glasses with display capabilities.

Learn more at global.rokid.com

AutoTrust AI Releases JEV-27B, an Open Decision Model for Self-Hosted AI Agents

Trained in about 9.2 hours on one NVIDIA B200, JEV-27B adds fast, calibrated System 1 decisions to a frozen Qwen3.8-27B backbone while preserving its System 2 generation path.

SINGAPORE, Sept. 29, 2026 /PRNewswire/ — AutoTrust AI today released JEV-27B, an Apache-2.0 open-weights model designed to handle frequent, structured decisions inside AI agent workflows while retaining the underlying model’s full generation and reasoning path.

JEV-27B answers yes/no, multiple-choice and 0–5 rating questions in a single forward pass and returns a calibrated probability for every option. It runs on one NVIDIA B200 inside a customer’s own infrastructure and serves both fast System 1 decisions and deliberate System 2 generation from a single set of weights.

The model trains a 108.9-million-parameter decision block—about 0.4% of the full model—on top of a frozen Qwen3.8-27B backbone. AutoTrust reports that training took approximately 9.2 B200-hours. With the decision block switched off, all 164 HumanEval completions were byte-identical to those produced by the base model.

“Jev proved there is real demand for models that decide rather than write,” said Daniel Tang, AutoTrust AI’s chief executive and co-founder. “JEV-27B shows that this capability can run on one GPU inside a customer’s own infrastructure, next to a reasoning model. For companies that cannot send every decision to a third-party API, that changes both the cost and the risk.”

Evaluation and evidence

AutoTrust AI evaluated JEV-27B across six public text-decision benchmark groups. It reported scores of 88.70% on JevBench, 83.75% on Kev, 73.89% on OpenJev text, 92.91% on Nimble, 77.46% on VitaminC and 87.71% on MASSIVE-en, for an equal-weight six-group mean of 84.07%.

For additional context, AutoTrust AI also ran the hosted TypeSafe Jev 1.13 API on the same benchmark groups and reported a six-group mean of 83.85%, with JEV-27B scoring higher on four groups and lower on two. Because AutoTrust conducted this comparison itself, the figures should be read as internal comparative evidence—not as an independent third-party validation or a claim of across-the-board superiority.

For public baseline context, AutoTrust reproduced the scores published by TokenRhythm for NeoHorse-Jev, Open-Jev, Kev and Laya English. AutoTrust did not rerun those four external baselines. The pinned source table is available at https://huggingface.co/TokenRhythm/NeoHorse-Jev-4B/blob/b50e043e22e0e41e7fc0c244e4daa707b8124930/README.md. These figures are included as published benchmark context rather than as a new same-environment comparison by AutoTrust.

JEV-27B was also evaluated for fidelity to its distillation target. On 25,376 held-out questions labeled with Jev 1.13 probability distributions, JEV-27B reported a mean KL divergence of 0.017, where zero means identical distributions. On decision-models-under-pressure, an independent benchmark scored against human labels, JEV-27B reached 96% of Jev 1.13’s accuracy with 16 answer options. In that independent test, JEV-27B approached—but did not exceed—Jev 1.13.

AutoTrust AI measured a median decision latency of 137 milliseconds and sustained throughput of about 130 decisions per second on one B200. The model card also cites third-party measurements of 238 to 301 milliseconds and 23 decisions per second for Jev’s hosted API. These are not controlled, like-for-like results: the hosted API measurements include network time, while AutoTrust AI’s local measurements do not, and the hardware, serving and concurrency conditions differ.

How it works

AutoTrust AI uses the terms System 1 for fast, typed decisions and System 2 for deliberate generation and reasoning. JEV-27B serves both from one set of weights. It follows JEV-9B as the company’s second integrated System 1 and System 2 open model.

The model is built with AutoTrust AI’s Blocks of Experts recipe. A strong pretrained model, Alibaba’s open-weights Qwen3.8-27B, stays frozen as one expert block. A small, detachable block is trained for a single skill, and a router sends each request either to the fast decision block or to the deliberate generation block.

The decision block holds 108.9 million trained parameters, 0.4% of the model, and took about 9.2 hours to train on one NVIDIA B200. The reasoning path was left untouched. With the decision block switched off, JEV-27B scores 78.0% on the HumanEval coding test, and all 164 of its completions are byte-identical to the base model’s.

In a demonstration reel released with the model, a self-hosted JEV-27B served as the decision engine for 10 tasks. It played Doom, making 64 decisions in a target-practice scenario, and steered a simulated drone through a MuJoCo obstacle course. It ran a live Google Flights search from Zurich to London and verified 21 results, navigated Wikipedia to Gödel’s incompleteness theorems, flagged four regression risks in a sample change to authorization code and routed a billing-refund ticket to support.

“Every AI agent is really a long chain of small decisions—which button to press, which file to open, which queue a ticket belongs in,” said Josh Liu, AutoTrust AI’s chairman and co-founder. “Make each one fast, private and cheap, and you change the economics of the whole chain.”

AutoTrust AI said JEV-27B inherits Jev 1.13’s blind spots, including multi-hop reasoning, arithmetic, dates and adversarial inputs, and that its training data is English-centric. The company says the model is not meant for high-stakes decisions and recommends gating its answers on confidence.

Benchmark context and source notes

Scores in percent. JEV-27B and TypeSafe Jev 1.13 measured by AutoTrust AI; NeoHorse-Jev, Open-Jev, Kev and Laya English are published baselines from TokenRhythm. Six-benchmark averages: JEV-27B 84.07%, TypeSafe Jev 1.13 83.85%, NeoHorse-Jev 77.70%, Open-Jev 75.67%, Kev 74.25%, Laya English 58.24%.
Scores in percent. JEV-27B and TypeSafe Jev 1.13 measured by AutoTrust AI; NeoHorse-Jev, Open-Jev, Kev and Laya English are published baselines from TokenRhythm. Six-benchmark averages: JEV-27B 84.07%, TypeSafe Jev 1.13 83.85%, NeoHorse-Jev 77.70%, Open-Jev 75.67%, Kev 74.25%, Laya English 58.24%.

Scores are in percent. JEV-27B and the hosted TypeSafe Jev 1.13 API were measured by AutoTrust AI; this is not third-party validation. NeoHorse-Jev, Open-Jev, Kev and Laya English are published baselines reproduced from TokenRhythm and were not rerun by AutoTrust. TokenRhythm source (pinned revision): https://huggingface.co/TokenRhythm/NeoHorse-Jev-4B/blob/b50e043e22e0e41e7fc0c244e4daa707b8124930/README.md. Full AutoTrust methodology and source notes: https://huggingface.co/autotrust/JEV-27B.

Availability

JEV-27B is available under the Apache-2.0 license at huggingface.co/autotrust/JEV-27B. The release includes the weights, decision adapter, training and serving code, vLLM support and full evaluation reports. A demonstration reel is available at https://huggingface.co/spaces/autotrust/JEV-27B-Demo.

AutoTrust AI plans to build the JEV decision block into future models in its Guru family, which powers the ScienceGuru research platform. ScienceGuru is available for Windows and macOS at https://scienceguru.ai/. AutoTrust AI also offers customized sovereign deployments for enterprises.

JEV-27B was trained on SargeDev/jev-distill-corpus-v3, a public, Apache-2.0-licensed corpus of Jev 1.13’s outputs. It shares no weights or code with, and is not affiliated with or endorsed by, TypeSafe AI. Jev and TypeSafe are trademarks of their respective owners.

About AutoTrust AI

AutoTrust AI Pte. Ltd. is a Singapore-incorporated AI research company building the Guru family of foundation models and ScienceGuru, an AI research platform for scientists and research teams. Its Blocks of Experts architecture combines pretrained expert blocks with small trained adapters to build frontier-capable and sovereign models efficiently. Learn more at autotrust.ai.

OCI Global Reports H1 2026 Results

AMSTERDAM, Sept. 29, 2026 /PRNewswire/ —

Hassan Badrawi, CEO of OCI Global commented:

“During the first half of 2026, OCI advanced the final stages of its strategic review. We completed the sale of our global ammonia distribution and terminal business to AGROFERT, handed over Beaumont New Ammonia to Woodside and monetized our entire investment in Methanex. In June, we reached agreement with AGROFERT for the sale of an initial 50% interest in OCI Nitrogen, expected to close in the second half of 2027, together with a mechanism for the subsequent sale of the remaining interest. The agreement provides a pathway for OCI Nitrogen to transition to a strategic owner with an established position in European nitrogen markets, supporting continuity for its employees, customers and operations.

Alongside these developments, and with the consent of the directors appointed by the Enterprise Chamber, we have convened an extraordinary general meeting at which shareholders will be asked to approve the proposed combination with Orascom Construction. The offer period for NNS’s recommended public cash offer for all OCI shares commenced on 15 September 2026, providing shareholders with a cash exit alternative, subject to the terms and conditions of the offer.

Throughout this process, our priorities remain maintaining operational discipline at OCI Nitrogen amid challenging market conditions, managing the Group’s remaining assets and obligations and completing the transactions required to conclude OCI’s strategic transformation.”

Basis of preparation

As of 30 June 2026, OCI’s remaining assets and liabilities, including OCI Nitrogen (“OCIN”), are classified as held for sale in connection with the proposed combination with Orascom Construction PLC (“Orascom Construction” or “OC”). With no continuing operations remaining, the Group’s results are presented entirely within discontinued operations, including results of disposed businesses up to their respective completion dates. The H1 2025 income statement and cash flow comparatives have been re-presented accordingly.

OCI has discontinued alternative performance measure (APM) adjustments, reflecting their reduced relevance to management’s assessment of underlying operating performance and strategic decision-making.

For further details of the Group’s financial performance and position, please refer to OCI N.V.’s published Semi-annual Report H1 2026, included as an appendix to this press release. 

Key Financial Highlights

H1 2026 Key Highlights

  • OCI Global (Euronext: OCI) reported net profit attributable to shareholders of USD 1 million in H1 2026, compared with USD 343 million in H1 2025. The H1 2026 result includes a USD 238 million gain on the disposal of OCI Ammonia Holding (“OCI AH”), largely offset by an impairment charge at OCI Nitrogen. The prior-year result included a USD 688 million gain on the sale of OCI Methanol.
  • The OCI Nitrogen segment reported revenue of USD 534 million in H1 2026, compared with USD 566 million in H1 2025[1]. Operating profit increased to USD 53 million from a loss of USD 21 million in the prior-year period, reflecting favorable market conditions in the beginning of the period, as more fully described below. Despite positive earnings during the first half of 2026, OCI Nitrogen reported negative free cash flow of USD 2 million. More recently, OCI Nitrogen has experienced increased margin pressure as higher European TTF gas prices have coincided with declining product selling prices and weaker demand in certain end markets. As a result, operating performance in July and August 2026 deteriorated materially relative to the levels achieved in H1 2026. Management estimates adjusted EBITDA and free cash flow for July and August 2026 of approximately USD 8 million and negative USD 16 million, respectively. Management’s outlook for the remainder of 2026 reflects a continuation of these less favourable market conditions.
  • OCI Nitrogen reported a net loss attributable to shareholders of USD 175 million in H1 2026, compared with a net loss of USD 12 million in H1 2025.
  • Prior to its classification as held for sale on 1 June 2026, OCI Nitrogen recognised a non-cash impairment charge of USD 215 million, which resulted in a June 30 carrying value of USD 123 million after management concluded that the carrying amount of the business exceeded its fair value less costs of disposal. The assessment reflected the impact of sustained geopolitical tensions, including elevated European natural gas prices, volatility in nitrogen markets and significant disruption at major on-site customers, which reduced customer operating rates and ammonia offtake.
  • Total corporate costs within Corporate Entities were USD 58 million in H1 2026, compared with USD 69 million in H1 2025. A substantial portion of H1 2026 costs related to strategic transactions, legal and advisory expenses, Enterprise Chamber proceedings and other costs associated with the Company’s ongoing transformation.

Net Cash Highlights

  • As of 30 June 2026, held-for-sale net cash was USD 1.05 billion. This compares with a net cash position of USD 695 million on 31 March 2026 and net debt of USD 54 million on 31 December 2025. The increase during H1 2026 primarily reflects receipts relating to the handover of Beaumont New Ammonia, net proceeds from the OCI AH disposal and the sale of Methanex shares. This was partially offset by corporate cash outflows, including one-off items, and a net cash outflow at OCI Nitrogen.

Key Strategic and Business Highlights

Proposed Combination with Orascom Construction and NNS Cash Offer

  • OCI continues to progress its proposed combination with Orascom Construction, announced on 9 December 2025 (the “Combination”). The Combination would establish an Abu Dhabi-anchored infrastructure and investment platform, combining OC’s construction and concessions expertise with OCI’s capital base and investment experience.
  • On 14 September 2026, NNS Holding (Cyprus) Limited (“NNS”) published its AFM-approved offer memorandum for its voluntary all-cash public offer to acquire OCI shares at EUR 4.10 per share, cum dividend (the “Offer”). The acceptance period opened at 09:00 CEST on 15 September 2026 and remains open, with a scheduled closing deadline of 17:40 CET on 17 November 2026, unless extended. The Offer has no minimum acceptance threshold and is subject to the terms and conditions set out in the Offer Memorandum.
  • OCI published its position statement on 15 September 2026, setting out the directors’ respective assessments of the Offer. The Independent Directors[2] unanimously recommend the Offer, on its terms and subject to its conditions, and continue to recommend the Combination. Their assessment was informed by independent advice, including Alvarez & Marsal’s solvent wind-down analysis and Rothschild & Co’s fairness opinion. They consider the Offer financially more attractive than a solvent wind-down but do not express a preference between tendering shares into the Offer and participating in the Combination. Shareholders are encouraged to make their own assessment, taking into account their individual circumstances and investment objectives.
  • The directors appointed by the Enterprise Chamber (the “EC Directors”) support the availability of the Offer as a cash alternative for shareholders, while maintaining a neutral opinion on the offer price. Their support does not constitute a recommendation to shareholders to tender their shares. Having assessed the Combination in conjunction with the Offer, the EC Directors consider that the two propositions together give adequate and reasonable weight to the interests of OCI’s minority shareholders. Their assessment was supported by separate financial and legal advice, including AXECO’s fairness opinion.
  • With the consent of the EC Directors, OCI has convened an extraordinary general meeting for 30 October 2026 (the “EGM”) to discuss the Offer and vote on the resolutions relating to the Combination. The resolutions relating to the Combination are subject to the conditions described in the EGM documentation, including conditions relating to the Offer. Further details are provided in the EGM agenda, explanatory notes and OCI’s position statement.
  • Following the hearing on 20 August 2026 in the proceedings initiated by VEB and certain other shareholders, OCI is awaiting the Enterprise Chamber’s decision, which is expected by 7 October 2026. These shareholders did not seek interim measures aimed at postponing, prohibiting or otherwise preventing completion of the Combination.
  • Completion of the Combination is currently expected in Q4 2026, subject to shareholder approval and satisfaction of applicable transaction conditions.

OCI Nitrogen

  • On 1 June 2026, OCI entered into an agreement with AGROFERT pursuant to which AGROFERT will acquire an initial 50% interest in Nitrogen Intermediate Holding B.V., the parent company of OCI Nitrogen B.V (“OCI Nitrogen”). Completion of the initial transaction is expected by H2 2027, subject to regulatory approvals, OCI shareholder approval and other customary closing conditions. The agreement also provides OCI with a put option and AGROFERT with a call option over the remaining 50% interest in OCIN, exercisable from two years after completion of the initial transaction.
  • OCI Nitrogen was classified as held for sale as of 1 June 2026, and the results of the European Nitrogen segment, including the Ammonia Distribution business, are presented as discontinued operations in accordance with IFRS 5.
  • Nitrogen market fundamentals were generally supportive through April 2026, when pricing moderated from peak levels reached earlier in the year. Market conditions deteriorated following the escalation of geopolitical tensions in the Middle East, which drove a significant increase in European natural gas prices without a corresponding increase in nitrogen product prices. As a result, a substantial divergence emerged between gas input costs and selling prices for the remainder of the period. These market conditions have persisted into Q3 2026. Average European natural gas prices in Q3 2026 to mid-September were approximately 40% higher than in Q2 2026, while average ammonia and CAN prices were approximately 20% and 10% lower, respectively, and significantly below the peaks reached in April.
  • In response to the current margin environment, OCI Nitrogen has reduced production at certain facilities and curtailed ammonia production where economics do not support full operating rates. Major on-site customers have also operated at significantly reduced rates during the period, contributing to lower ammonia offtake, reduced asset utilisation and materially higher per-unit operating costs.
  • Conditions in the melamine market have been particularly challenging, with weakened demand, lower operating rates and continued pressure on profitability. On this basis, OCI Nitrogen has prioritised production of higher-return products, including UAN and AdBlue, and continues to assess alternative operating configurations for its melamine assets.
  • In addition to challenging market conditions, earnings were affected by operational disruptions at certain production facilities and major on-site customers during the period. OCI Nitrogen continues to operate in a highly cyclical and operationally leveraged environment, where relatively small changes in natural gas costs, product pricing, plant reliability and customer operating rates can have a disproportionate impact on profitability, cash generation and valuation.

Beaumont New Ammonia

  • On 25 March 2026, OCI completed the handover of Beaumont New Ammonia to Woodside and received the USD 470 million deferred consideration, representing 20% of total transaction proceeds, less amounts withheld in respect of outstanding construction obligations, certain closing-related adjustments and remaining estimated close-out costs. OCI has since substantially completed the project close-out process, including the settlement of all subcontractor claims. OCI continues to estimate total project costs through completion at approximately USD 1.8 billion, consistent with Q4 2025. This total budget is inclusive of all close-out costs and the H2 2026 final settlement.

OCI Ammonia Holding

  • On 31 March 2026, OCI completed the sale of its entire equity interest in OCI AH to AGROFERT, receiving initial cash proceeds of EUR 297 million (USD 342 million). The transaction remains subject to customary post-closing adjustments, with completion of the settlement process expected in H2 2026. OCI does not currently expect those adjustments to have a material impact on future cash flows.

Methanex Investment

  • During H1 2026, OCI fully monetized its holding of 9,944,308 Methanex shares through a series of block sales, generating total cash proceeds of approximately USD 543 million after customary fees and expenses. The shares represented approximately 12.9% of Methanex’s outstanding share capital when received as consideration for the sale of OCI Methanol in June 2025. The net weighted average sale price was USD 54.56 per share, 21% above the reference share price used in the OCI Methanol transaction announced in September 2024.

Fertiglobe Contingent Consideration and Liabilities

  • There have been no material developments that impact the Fertiglobe contingent consideration. Accordingly, the provision remains unchanged from the position reported in the audited 2025 annual accounts. The Board continues to believe that the provision of USD 361.6 million represents the best estimate of OCI’s potential exposure.

Other Information

Notes

This report contains unaudited first half financial highlights of OCI N.V. (“OCI Global”, “OCI”, the “Group” or the “Company”), a public limited liability company incorporated under Dutch law, with its head office located at Honthorststraat 19, 1071 DC Amsterdam, the Netherlands.

OCI Global is registered in the Dutch commercial register under No. 56821166 dated 2 January 2013. The Group is primarily involved in the production of nitrogen-based fertilizers and industrial chemicals.

Auditor

The information contained in this Results Report has not been audited. The accompanying Semi-Annual Condensed Consolidated Financial Statements have been reviewed, but not audited, by the Company’s independent external auditor.

Market Abuse Regulation

This press release contains inside information as meant in clause 7(1) of the Market Abuse Regulation.

About OCI Global

Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.

OCI stock symbols: OCI / OCI.NA / OCI.AS

[1] Financial performance for OCI Nitrogen in H1 2025 includes the results of OCI Ammonia Distribution B.V. prior to its carve-out in August 2025 and is therefore not fully comparable to H1 2026.
[2] “Independent Directors” means OCI’s directors other than Nassef Sawiris, Nadia Sawiris and the directors appointed by the Enterprise Chamber, and includes the Company’s executive director.

 

H1 2026 Results Report and Financial Statements
H1 2026 Results Report and Financial Statements

Regent Pacific (0575.HK)’s Deep Longevity Launches Accrua™ US Consumer Digital Health and Telehealth Platform

Available Across All 50 US States, Extending Deep Longevity’s AI-Powered Ageing Science Directly to Consumers for a Second Growth Curve

HONG KONG, Sept. 28, 2026 /PRNewswire/ — Regent Pacific Group Limited (“Regent Pacific” or the “Company“, together with its subsidiaries, the “Group“; stock code: 0575.HK), is pleased to announce that Deep Longevity, its AI-powered biological ageing intelligence subsidiary, will launch Accrua™ (“Accrua“), its consumer digital health and telehealth platform, in the United States (“US“) in October 2026. From launch, Accrua will be available to consumers across all 50 US states offering personalised clinician-guided care anchored to each user’s biological age rather than symptoms alone.

Accrua represents an important step in Deep Longevity’s direct-to-consumer (“D2C”) strategy for the US market, complementing the Group’s existing business-to-business (“B2B”) relationships with clinics, hospitals, laboratories and insurance companies. It marks the first time Deep Longevity’s proprietary and award-winning ageing-clock technology and SenoClock® platform have been extended directly to consumers, and the Board regards it as a significant new source of future revenue for the Group.

About Accrua

Accrua provides medical care online that is simple, direct and led by licensed US clinicians. At the heart of the platform is Deep Longevity’s proprietary, AI-generated BloodAge report, which uses a routine blood test to indicate whether a consumer is a “faster ager” — someone whose biological age is advancing more quickly than their chronological age.

Following a clinician consultation, Accrua offers doctor-guided access to a range of treatment categories, including medications for weight loss (such as glucagon-like peptide-1 (“GLP-1“) therapies), peptides, women’s health (such as hormone replacement therapy) and men’s health (such as testosterone therapies). Each treatment plan is personalised by a licensed clinician and anchored to the user’s BloodAge report — rather than to self-reported symptoms or a single biomarker — with BloodAge re-measured quarterly so users and their clinicians can track progress against an objective, science-based measure of biological ageing.

Built around the proposition — “You know your age. Your blood knows better.” — Accrua integrates quarterly biological age measurement, clinician-guided treatment and compounded therapies into an integrated longevity care programme backed by peer-reviewed science. Deep Longevity’s BloodAge model was the subject of a peer-reviewed study (Goshen et al., Aging and Disease, 2026) following approximately 2,600 adults over an average of 9.2 years, which found that each additional year of gap between biological and chronological age was associated with a 15% increase in mortality risk. Deep Longevity’s technology was also recently named Runner-Up in the Nestlé VITAL Smart Aging Global Challenge, a global innovation competition drawing entries from 150 companies.

A Large and Fast-growing Market

Accrua is entering a US consumer digital health market in which platforms addressing adjacent categories have achieved substantial revenue. MEDVi, LLC, a US digital telehealth platform focused on GLP-1 weight-loss and related therapies, generated over US$400 million in revenue in 2025, its first full year of operation, and was on track for an approximately US$1.8 billion revenue run-rate in 2026, as reported by The New York Times (2 April 2026) and Forbes (2 April 2026, citing The New York Times). While no assurance can be given that Accrua will achieve comparable results, the Board believes these figures illustrate the scale of consumer demand and the revenue potential of the market Accrua is designed to address.

Capital-efficient, Scalable Business Model

Accrua* has been built on a capital-efficient, scalable model. Clinical delivery will be provided through established US telehealth infrastructure partners and a network of independent, licensed physicians and pharmacy and compounding partners, covering consultations, prescriptions, pharmacy fulfilment, patient intake and billing across all 50 US states — allowing Deep Longevity to scale nationally from launch without owning clinical infrastructure or carrying drug inventory directly. This approach will minimize upfront capital requirement for expansion while maintaining operational flexibility. Revenue is expected to be largely subscription-based and recurring in nature. The platform operates on HIPAA-compliant infrastructure and will be LegitScript certified ahead of launch. The launch will be supported by targeted digital marketing, initially focused on selected US states, with the aim of optimising customer acquisition before further scaling.

Mr. Jamie Gibson, Executive Director and Chief Executive Officer of the Company, commented: “The launch of Accrua is a landmark moment for Deep Longevity and for the Group. For the first time, consumers across the US will be able to access our BloodAge science directly, with personalised care from licensed clinicians. We believe anchoring treatment to biological age — rather than to symptoms alone — is a genuinely new proposition in a market that has already demonstrated exceptional consumer demand, and we are excited about the opportunity ahead.”

*Accrua is a newly launched business, and the revenues to be generated from it, if any, remain uncertain and will depend on a number of factors, including consumer demand, competition and the regulatory environment for digital telehealth in the US.

About Deep Longevity

Deep Longevity is an AI-powered biological ageing intelligence company dedicated to making healthy ageing measurable and actionable. Its proprietary ageing clock technology — validated through peer-reviewed science and published in leading international journals — measures biological and cognitive ageing across multiple physiological systems, enabling healthcare and consumer health organisations to integrate personalised ageing intelligence into their products and services. For more information, visit www.deeplongevity.com.

About Regent Pacific Group Limited (Stock code: 0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders since its initial public offering in May 1997.

www.regentpac.com

The English version of this press release shall prevail in case of any discrepancy or inconsistency between the English version and its Chinese translation.

HCLSoftware to Acquire Robotiq.ai, Strengthening Enterprise Agentic Automation

Acquisition adds enterprise RPA capabilities to HCL UnO Agentic, strengthening end-to-end orchestration across AI agents and enterprise applications

SANTA CLARA, Calif., Sept. 28, 2026 /PRNewswire/ — HCLSoftware (NSE: HCLTECH) (BSE: HCLTECH), the software business division of HCLTech, today announced its intent to acquire Robotiq.ai, a provider of Enterprise Robotic Process Automation (“RPA”) platform, based in Zagreb, Croatia.

HCLSoftware is seeing growing enterprise demand for AI systems that not only reason but execute work reliably across complex business environments. Robotiq.ai adds enterprise RPA capabilities that allow AI-driven workflows to automate tasks in applications where APIs are unavailable or insufficient, extending HCL UnO Agentic’s orchestration capabilities from decision-making to execution.

Robotiq.ai’s RPA platform is used in large banks, insurance groups and telecom providers and is built with ISO-certified security, audit logs, and flexible deployment options making the platform reliable and secure.

“Enterprises are looking beyond AI experimentation toward production-scale automation that is secure, governed and reliable,” said Kalyan Kumar, President, HCLSoftware. “Robotiq.ai strengthens HCL UnO Agentic by combining orchestration with enterprise-grade execution, helping customers confidently deploy and scale agentic AI across their operations.”

“We built Robotiq.ai on a simple belief: automation should be useful, fast to deploy, and reliable in production,” said Darko Jovišić, CEO & Co-founder, Robotiq.ai. “Joining HCLSoftware gives our technology the enterprise reach, scale, and platform. Together with HCLSoftware, customers get automation that doesn’t stop at the task — it becomes part of an orchestrated, governed process across the entire enterprise.”

The acquisition is expected to close in November 2026.

About HCLSoftware 

HCLSoftware is a global leader in software innovation, dedicated to powering the Digital+ economy. We develop, market, sell and support transformative solutions that combine and integrate experience, data, and operations, delivering on a bold, AI-driven vision of the Digital+ future. Built on a rich heritage of pioneering spirit and unwavering commitment to customer success, we deliver best-in-class software products that empower organizations to achieve their goals. Our core values of integrity, inclusion, value creation, people-centricity and social responsibility guide everything we do. HCLSoftware serves more than 20,000 organizations including majority of the Fortune 100 and almost half of the Fortune 500. To learn more, visit hcl-software.com.

For further details, please contact:

Jeremy McNeive, HCLSoftware
jeremy.mcneive@hcl-software.com 

Ashutosh Sharma, HCLTech
ashutosh.sharma@hcltech.com

More Than a Stylus: How Hands-On Experiences Are Changing the Way Consumer Electronics Are Presented

BERLIN, Sept. 28, 2026 /PRNewswire/ — At IFA 2026 in Berlin, visitors encountered the usual showcase of processors, displays, connected devices and technical specifications. But at the Metapen booth, the emphasis was less on watching technology and more on using it.

Visitors try Metapen styluses at IFA 2026 in Berlin
Visitors try Metapen styluses at IFA 2026 in Berlin

The approach reflects a broader change in consumer electronics. As products become more sophisticated, specifications alone do not always communicate their value. For many consumers, the first few seconds of using a product can be more revealing than a presentation.

A stylus is a good example. Its physical form is familiar, but its applications extend beyond traditional writing. Children can draw and explore digital creativity; students can take notes and annotate documents; professionals can sketch ideas, sign documents or work directly on a tablet.

At Metapen’s IFA booth, one young visitor provided a simple illustration. A girl picked up a stylus and began interacting with the screen while her family watched nearby. There was no complicated explanation required. She simply started creating.

That interaction highlights an important principle in product design: technology does not always need to demand attention. When a stylus responds naturally, users can focus on what they want to write, draw or create rather than on how technology works.

Metapen has built its business around the stylus category, developing products for devices including iPad, Surface and Chromebook. Its lineup covers everyday digital writing as well as pressure-sensitive applications for drawing and creative work. The company focuses on making digital writing and creation more accessible through functionality, design and affordability.

This positioning reflects how the stylus market is evolving. Rather than treating a pen simply as an accessory to a tablet, Metapen presents it as part of the user experience—the point where hardware, software and human creativity meet.

The opportunity goes beyond the stylus. As digital learning, work and creative activities become part of everyday life, products that make technology feel more natural can play an increasingly important role.

IFA remains a place for companies to demonstrate technical innovation. But moments like the one at Metapen’s booth suggest another way of evaluating technology: not only by what is inside a product, but by what happens when someone picks it up for the first time.

Sometimes, the most convincing product demonstration is simply watching someone use it—and enjoy the experience.

Brooklyn Sports & Entertainment Names Alibaba Group an Official Technology and Cloud Partner of the Brooklyn Nets

Alibaba to become Nets’ Official Jersey Patch Partner, and bring Real-Time 360° Replay and personalized fan collectibles to Barclays Center

NEW YORK, UNITED STATES – Media OutReach Newswire – 28 September 2026 – Alibaba Group and Brooklyn Sports & Entertainment today announced a strategic multi-year partnership naming Alibaba an Official Technology and Cloud Partner of the Brooklyn Nets. The partnership pairs Alibaba’s cloud technology with the Brooklyn Nets’ live game replay, in-game entertainment and marketing initiatives, creating more immersive experiences for fans in the arena.

As the Nets’ Official Jersey Patch Partner, Alibaba will support the team’s 60th anniversary season—a year-long campaign honoring iconic players, defining moments and milestones across the franchise’s history—through technology-enabled fan experiences and marketing activations.

“Alibaba has long partnered with leading sports organizations worldwide, giving us a deep understanding of how to deliver technology at the scale and speed live sports demand,” said Toby Xu, Chief Financial Officer, Alibaba Group. “We are excited to team up with the Brooklyn Nets to unlock new possibilities in sports innovation. As we head into the new season, we look forward to delivering immersive experiences for fans at Barclays Center and beyond.”

“The Brooklyn Nets are committed to investing in technology to enhance the fan experience and elevate how basketball is experienced at Barclays Center,” said Sam Zussman, CEO, Brooklyn Sports & Entertainment. “As we celebrate 60 seasons of Nets basketball, we are intentional about how we innovate across our marketing and in-arena experiences, and this partnership with Alibaba will help us develop new ways to connect fans with our history and identity.”

Beginning with the 2026-27 NBA season, Alibaba’s technology will power a Real-Time 360° Replay system at Barclays Center, bringing faster and more innovative replays. Through the in-arena “Nets Figure Lab,” fans will also be able to create personalized collectible cards using Alibaba’s technology.

Across the season, Alibaba and the Nets will use the partnership to test and scale innovative technology and marketing applications on and beyond game day, enhancing fan experiences while supporting the next chapter of Nets basketball. For the Nets, the collaboration represents an investment in the future of the franchise, using technology and creative collaboration to honor six decades of history while building what comes next.

Hashtag: #AlibabaGroup

The issuer is solely responsible for the content of this announcement.

Vitals Announces Expansion to Singapore and Hong Kong as Bruce Rockowitz Highlights Thailand’s Wellness Model

HONG KONG SAR – Media OutReach Newswire – 28 September 2026 – Vitals today announced that it is extending its data-driven wellness model to Singapore and Hong Kong. The move expands a platform built around testing, interpretation, telehealth and recurring products into additional Asian markets.

Vitals is a diagnostics-led health and wellness platform founded and led by Charles Temple, a New Zealand entrepreneur with more than 18 years of operating experience in Hong Kong and Southeast Asia. Its proposition is straightforward: rather than asking consumers to guess which vitamins, supplements or lifestyle changes they need, test first, interpret the results properly and build the recommendation around the individual.

The entry point is testing, and Vitals has made it deliberately easy. Its Comprehensive Wellness Test is non-invasive: a small hair sample collected at home is analyzed using German technology to screen more than 700 biomarkers spanning nutritional, metabolic and systemic indicators. For customers who want clinical-grade data, Vitals Longevity blood programs — Essential Wellness, Advanced Vitality and Executive Longevity — cover up to 82 laboratory indicators, with a licensed nurse drawing the sample at the customer’s home or office. Samples are processed by partner laboratories certified to ISO 15189 and by the Ministry of Public Health, and customers can add individual tests to any program.

Results are delivered digitally through the Vitals platform, where an AI analysis layer, working with the laboratory and the company’s clinical team, turns raw values into a personalized report and a recommended protocol. Vitals is rolling out online consultations with licensed doctors for interpreting blood results, general health questions and, over time, physician-supervised programs, so that the customer does not have to bridge the gap between data and decision alone.

“Thailand offers a useful case study in how traditional consumer categories can be rebuilt around data,” said Bruce Rockowitz, spokesperson for Vitals. The Vitals model connects testing, interpretation, medical advice, recommendations and recurring products into a single digital relationship.

Thailand already has many of the ingredients required for a wellness economy: a sophisticated healthcare sector, accredited laboratories, a strong tourism industry, established hospitality infrastructure and consumers increasingly familiar with premium health and beauty products. The personalized testing and supplements market in Thailand is forecast to grow from about $80 million in 2026 to $124 million by 2033, according to Grand View Research.

Vitals extends its data-driven wellness model across Asia

Vitals’ own-brand supplement range is developed using the company’s formulations, produced by third-party manufacturers in Thailand and independently tested. It sits alongside more than 100 global and local brands sold through Vitals’ retail stores and online platform. Because every recommendation traces back to the customer’s own results, the company can stay in contact to retest, refine the protocol and refill rather than relying on one-off purchases.

Vitals is now extending its model to Singapore and Hong Kong. The same logic can extend beyond supplements into hospitality, food, beauty, travel and healthcare, where adding data, personalization and digital distribution can potentially turn traditionally service-based businesses into recurring consumer platforms.

For more information about Vitals, visit: https://vitals.co.th/en

Hashtag: #Vitals

The issuer is solely responsible for the content of this announcement.

About Vitals

Vitals is a diagnostics-led health and wellness platform with physical stores and an online platform. It offers non-invasive hair-based wellness testing of more than 700 biomarkers, at-home blood testing with licensed nurse collection and certified laboratory analysis, AI-generated personalised reports and protocols, online consultations with licensed doctors, and a supplement marketplace combining its own third-party-tested range with more than 100 global and local brands.

Media Contact
Vitals
Media enquiries: info@vitals.co.th
Website: https://vitals.co.th/en